In Brief: Sepracor levalbuterol
Executive Summary
Sepracor levalbuterol: NDA filed July 1. Data from a 362-patient four-week study show that patients on inhaled levalbuterol .63 mg generally showed a lower incidence and severity of beta-mediated side effects, such as increased pulse rate and lowered potassium levels, than did patients receiving racemic albuterol 2.5 mg...